MiRNAs regulate cancer cells, but their potential effects on cancer stem/progenitor cells are still being explored. In this study, we used quantitative real-time-PCR to define miRNA expression patterns in various stem/progenitor cell populations in prostate cancer, including CD44
Introduction
Most tumors contain a dynamic population of less differentiated and highly tumorigenic cells operationally defined as cancer stem cells (CSC) or tumor-initiating cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . CSCs may be phenotypically purified using surface markers. CD44 is one such marker widely used to enrich tumor-initiating cells, for example, in cancers of the breast (2), pancreas (5), head and neck (8) , colon (9) , and the prostate (6, 7). Our previous work has shown that CD44 þ cells from prostate cancer cell cultures or prostate cancer xenografts exhibit high proliferative and clonogenic potential in vitro. Moreover, using limiting dilution assays in NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice, we find that CD44 þ prostate cancer cells possess 6 to 30 times higher tumor-regenerating capacity than CD44 À cells (6, 7) . CD133 has similarly been used to enrich
CSCs in brain (3), colon (10) , and other cancers. Several surface marker-independent strategies have also been used to enrich tumor-initiating cells (1) . Side population assay is a flow cytometry-based method initially developed to enrich hematopoietic stem cells owing to their expression of high levels of drug-detoxifying surface transporter proteins such as ABCG2 and MDR1 that efficiently efflux the Hoechst dye 33342 (11) . Using the side population technique, we have shown that the side population cells in LAPC9 xenografts, although representing only approximately 0.01% of the total tumor cell population, are more than 500-fold more tumorigenic than the isogenic non-side population cells (12) . With the preponderant evidence for CSCs and our increasing knowledge of CSC heterogeneity (1) , it becomes apparent that we need to understand how tumorigenic cancer cells are regulated at the molecular level so that we can design CSCspecific therapeutics. MiRNAs are small noncoding RNAs that regulate many biologic processes by inhibiting the target mRNA translation or stability (13) . Deregulation of miRNAs has been observed in a variety of human tumors (14, 15) . In prostate cancer, several groups have conducted miRNA expression profiling studies using either miRNA microarray (16) (17) (18) (19) (20) or whole-genome deep sequencing (21) in prostate cancer cell lines, xenografts, or patient samples. These studies, although reporting prostate cancer-related miRNA alterations and shedding light on differential miRNA expression in prostate cancer (relative to benign tissues), have all been conducted in bulk tumor cells and thus fail to address alterations of miRNA expression and functions specifically in tumorigenic prostate cancer cell subsets. We recently conducted, for the first time, an miRNA expression profiling in 6 highly purified prostate cancer stem/progenitor cell populations and reported that miR-34a, a p53 target, was underexpressed in all these populations (22) . We further showed that miR-34a negatively regulated prostate CSC (PCSC) activity and inhibited prostate cancer metastasis by directly repressing CD44 (22) . Herein, we present detailed miRNA expression profiling procedures and results and report the miRNAs that are commonly and differentially expressed in prostate cancer stem/progenitor cell populations. We further investigate the biologic functions of 2 commonly altered miRNAs, that is, let-7, and miR-301, in the context of regulating CSCs and prostate cancer regeneration. Finally, using miR-34a as an example, we explore potential mechanisms that may be responsible for the differential miRNA expression in prostate cancer stem/progenitor cells. Our results converge with the emerging theme that distinct miRNAs coordinately and distinctively regulate CSC properties (23) .
Materials and Methods
Many basic experimental procedures have been described in our earlier publications (6, 7, 12, 22, (24) (25) (26) . Some experimental procedures are described in Supplementary Methods. Primary human prostate tumors (HPCa) used in this study are presented in Supplementary Table S1 . were maintained in NOD/SCID mice. NOD/SCID mice were produced mostly from our own breeding colonies and purchased occasionally from the Jackson Laboratories and maintained in standard conditions according to the Institutional Guidelines. All animal experiments were approved by our Institutional Animal Care and Use Committee. All these 6 prostate cancer cell types were routinely checked to be free of mycoplasma contamination using the Agilent MycoSensor QPCR Assay Kit (cat. #302107). Cell authentification by DNA fingerprinting is under way.
Transient transfection with oligonucleotides
Prostate cancer cells were transfected with 30 nmol/L of miR-34a, let-7a, let-7b, or miR-301 mirVana mimics, or nontargeting negative control miRNA (miR-NC) oligos (Ambion) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions (22) . MirVana mimics are synthetic double-stranded oligonucleotides (oligos) that mimic mature miRNAs. In some experiments, mirVana miRNA inhibitors, chemically modified antisense oligos against let-7b, miR-301, or miR-NC (Ambion) were introduced into prostate cancer cells using the same conditions. After culturing overnight for 48 hours, transfected cells were harvested for in vitro and in vivo studies.
Lentiviral-mediated overexpression of let-7a
pLL3.7-let-7a and pLL3.7 control vector were kindly provided by Dr. J. Lieberman (Harvard University, Cambridge, MA; ref. 27 ). Lentiviruses were produced in 293FT packaging cells and titers determined for GFP using HT1080 cells (22) . Prostate cancer cells were infected with the lentiviral supernatant [multiplicity of infection (MOI), [5] [6] [7] [8] [9] [10] in the presence of 8 mg/mL polybrene and harvested 48 to 72 hours after infection for experiments.
Statistical analyses
In general, the unpaired 2-tailed Student t test was used to compare differences in cell numbers, cumulative population doublings, percentages of CD44 þ cells, percentage of bromo- (28) . In addition to these 5 (i.e., 3 CD44 þ , 1 CD133 þ , and 1 a2b1 þ ) prostate cancer cell populations, we also purified, from the LAPC9 tumor, the side population, which harbors great tumor-regenerative activity (12) . Because the side population represents less than 0.1% of the total population in LAPC9 tumor (12), we manually curated 57 miRNAs (Supplementary Table S4 ) that could be reliably detected and compared with their expression levels in the side population versus non-side population cells ( Supplementary Fig. S1 , step III). Comparisons of 6 marker-positive and -negative prostate cancer cell populations revealed interesting and informative differences in miRNA expression patterns. Tables S3 and S4 ). Interesting, the top overexpressed miRNA in CD133 þ LAPC4 cells was miR-21, one of the best-characterized oncomiRs widely overexpressed in human cancers (45) . Among the top 10 downregulated miRNAs were many miRNAs that were also underexpressed in CD44 þ prostate cancer cells and several tumor-suppressive miRNAs including miR-133a, miR-126, miR-15a, and miR-200a (Fig. 1A) . In general, the magnitude of downregulation (i.e., to $10 À6 ) was much more pronounced than that of upregulation (up to $10 2 for most), although surprisingly, there were more miRNAs overexpressed than underexpressed in CD133 þ LAPC4 cells (Fig. 1A) Fig. S3A ).
In contrast to CD133 þ prostate cancer cells, there were significantly more miRNAs underexpressed than overexpressed in LAPC9 side population cells when compared with the isogenic non-side population cells and, again, the levels of downregulation were higher than those of upregulation (Fig.  1B) . The top overexpressed miRNA was miR-451, which was recently shown to regulate the self-renewal and tumorigenicity of colorectal CSCs (46) . Among the top 10 underexpressed miRNAs in side population were miR-15a/15b and several oncosuppressive miRNAs downregulated in CD44 þ prostate cancer cells. We observed 6 commonly overexpressed and 31 commonly underexpressed miRNAs in side population versus CD44 þ LAPC9 cells ( Supplementary Fig. S3B ). Finally, roughly similar numbers of up-and downregulated miRNAs were observed in a2b1 þ and a2b1 À Du145 cells (Fig. 1C) . We observed 44 commonly overexpressed and 22 commonly underexpressed miRNAs in a2b1 þ versus CD44 þ Du145 cells ( Supplementary Fig. S3C) . Surprisingly, among the top 10 upregulated miRNAs were miR-30a-5p, let-7a, and miR-196a (Fig. 1C ), which were commonly underexpressed in CD44 þ prostate cancer cells (Table 1 ). These observations are consistent with our earlier conclusions that the a2b1 þ prostate cancer cell population overlaps with but is also distinct from the CD44 þ population (7).
Subsequently, we tried to identify commonly changed miRNAs. We first compared the common CD44 profiles (Table 1) with the profiles generated from CD133 þ or a2b1 þ populations (Supplementary Tables S2 and S3 ) and uncovered the miRNAs that were commonly over-or underexpressed in the 4 (i.e., 3 CD44 þ together with CD133 þ or a2b1 þ ) cell populations (Table 2 ). When we combined 5 populations (i.e., 3 CD44 þ together with CD133 þ and a2b1 þ ), only 4 miRNAs, that is, let7b, miR-106a, miR-141, and miR-34a, were commonly underexpressed and 2 miRNAs, that is, miR-301 and miR-452, were commonly overexpressed ( Fig. 2A ; Table 2 ). When we further included the expression profile from the LAPC9 side population, only one miRNA, that is, miR-34a, was commonly underexpressed and one miRNA, miR-452, was commonly overexpressed in all 6 prostate cancer cell populations (Table 2 ; Supplementary Fig. S4A ).
Validation of commonly changed miRNAs in patient tumor (HPCa)-derived CD44 þ cells
The preceding miRNA library expression profiling was conducted in cells purified from 3 xenograft models. To validate the miRNA expression data, we purified CD44 þ and CD44 À prostate cancer cells from 21 primary HPCa samples (Supplementary Table S1 ) and measured the levels of 4 commonly underexpressed (miR-34a, let-7b, miR-141, and miR-106a) and 2 commonly overexpressed (miR-301 and miR-452) miRNAs. This strategy has an additional advantage of establishing the potential clinical relevance. We previously verified miR-34a underexpression in all HPCa-purified CD44 þ prostate cancer cells (22) . let-7b also showed underexpression in the majority (18 of 21) of samples in the CD44 þ HPCa cells (Fig. 2B) .
Likewise, miR-141 was detected at much lower levels in CD44 þ than in CD44 À cells derived from most HPCa samples (data not shown). In contrast, miR-106a was underexpressed in 3 of the 5 xenograft-derived populations ( Supplementary Fig. S4B ) and in only approximately 50% of 21 HPCa-derived CD44 þ prostate cancer cells (Supplementary Fig. S4C ). With the 2 commonly overexpressed miRNAs, we detected an overrepresentation of miR-301 in the CD44 þ cells in 18 of 21 HPCa samples (Fig. 2C) .
Unexpectedly, although miR-452 was dramatically upregulated in 4 of the 5 xenograft populations ( Supplementary Fig. S4D ), it was downregulated in most CD44 þ HPCa cells ( Supplementary   Fig. S4E ). Altogether, of the 6 miRNAs commonly changed in the 5 prostate cancer cell populations, we could corroborate the underexpression of miR-34a, let-7b, and miR-141 and overexpression of miR-301 (i.e., 4 of 6 or 67%) using primary tumor-derived CD44 þ HPCa cells.
let-7 inhibits clonal and sphere formation in prostate cancer cells: differential effects from miR-34a To investigate the biologic functions of commonly and differentially expressed miRNAs, we first focused on 2 underexpressed miRNAs, that is, miR-34a and let-7, mainly because both had been shown to possess strong tumor-suppressive functions in other systems (27, 29, 30) . Our earlier studies showed that miR-34a functioned as a negative regulator of PCSCs and prostate cancer metastasis (22) . Herein, we focused on let-7 as 4 let-7 miRNA family members were underexpressed in CD44 þ cells (Table 1 ) and let-7b was commonly underexpressed in 5 prostate cancer cell populations ( Fig. 2A) as well as in CD44 þ HPCa cells (Fig. 2B) . Overexpression of let-7b in Du145 cells by transfection of a let-7b mimicking oligonucleotide reduced cell number (Fig. 3A) due to inhibition of proliferation as assessed by BrdUrd incorporation assays (Fig.  3B ). In addition, let-7b oligos, when compared with the negative control (NC) oligos that contain a scrambled sequence, inhibited the establishment of Du145 holoclones ( Fig. 3C-E) and spheres (Fig. 3F ). Prostate cancer cell holoclones contain self-renewing tumor-initiating cells (24) and prostate cancer cell spheres formed under anchorage-independent conditions harbor tumor-initiating cells (6, 12, 25) . Finally, when we infected Du145 cells with a lentivirus (i.e., pLL3.7-let-7a; ref. 27 ) that encodes let-7a (which recognizes the same seed sequence as let-7b), both clonal development ( Supplementary Fig. S5A ) and sphere formation ( Supplementary Fig. S5B and S5C) were inhibited. We observed similar inhibitory effects of let-7b oligos in another prostate cancer cell type, PPC-1 ( Fig. 3G ; Supplementary Fig. S6A-S6C ). It should be noted that all miRNA mimicking oligos used in our previous (22) and present studies are mature miRNAs, which mimic the dicer cleavage product loaded into the RNA-induced silencing complex (RISC) in the cytoplasm (22) . Overall, let-7b mimicking oligos showed similar inhibitory effects to miR-34a overexpression on prostate cancer cell holoclones and spheres ( Fig. 3C-G; Supplementary Fig. S6B  and S6C ). However, when we analyzed cell-cycle profiles in PPC-1 cells treated with miR-34a or let-7b oligos, we observed that miR-34a caused G 1 cell-cycle arrest, whereas let-7b led to prominent G 2 -M phase arrest ( Fig. 3H and I ). Fully consistent with the differential effects between miR-34a and let-7b on cell cycle, miR-34a overexpression induced significantly increased cell senescence assessed by staining of prostate cancer cells for senescence-associated b-gal (SA-bgal) activity ( Fig. 3J ; Supplementary Fig. S6D ). It is well documented that G 1 cell-cycle arrest generally precedes cell senescence. In contrast, let-7b oligos, which did not cause G 1 arrest, did not induce PPC-1 cell senescence ( Fig. 3J; Supplementary Fig. S6D ). These results altogether suggest that let-7b and miR-34a exert differential mechanisms in prostate cancer cells with respect to their effects on cell cycle and senescence. let-7 inhibits prostate tumor regeneration: evidence for fast turnover of let-7 in prostate cancer cells Next, we investigated the let-7 effects on tumor regeneration. We first conducted the "positive" control experiments by s.c. implanting A549 lung cancer cells that had been Fig. S7A) . Surprisingly, in multiple similar tumor experiments carried out in Du145 ( Supplementary Fig. S7B and S7C) or LAPC9 ( Fig. 4A ; Supplementary Fig. S7D ) cells, let-7b oligos did not manifest obvious tumor-suppressive effects whether cells were implanted s.c. or in the dorsal prostate (DP; Supplementary  Fig. S7B and S7C ). Similar to let-7b oligos, let-7a oligos also did not inhibit LAPC9 tumor regeneration, although miR-34a oligos significantly retarded tumor growth (Fig. 4A) . These surprising results suggested that (i) let-7 miRNAs might exert differential effects on lung (A549) versus prostate (Du145 and LAPC9) cancer cells; (ii) transfected let-7 oligos might be turned over faster in prostate cancer cells compared with lung cancer cells; (iii) let-7 and miR-34a might exert divergent regulatory roles in prostate cancer cells; and/or (iv) let-7 oligos might become degraded or turned over faster than miR-34a oligos in prostate cancer cells.
To start addressing these possibilities, we first measured let-7a/b and miR-34a levels in both freshly transfected cells and endpoint tumors (Fig. 4B-D) . Du145 (Fig. 4B) and LAPC9 (Fig. 4C ) cells transfected with let-7 oligos had several 100-fold higher levels of let-7 than the same cells transfected with NC oligos at 48 hours. Unexpectedly, however, A549 cells transfected with the same amount (i.e., 30 nmol/L) of let-7b possessed much higher levels of intracellular let-7b than either Du145 or LAPC9 cells (Fig. 4B and C) . More surprisingly, at 48 hours after transfection of the same amount of miR-34a or let-7b (30 nmol/L for each), LAPC9 cells retained significantly higher levels of miR-34a than let7b (Fig. 4C) . As expected, the endpoint tumors all expressed similarly low levels of let-7a/b or miR-34a (Fig. 4D) . These results suggest that transfected let-7 oligos, in contrast to miR-34a oligos, were rapidly degraded in prostate cancer cells, in contrast to A549 cells. Consistent with this suggestion, when we infected LAPC9 cells with pLL3.7-let-7a, the continuously delivered let-7a significantly slowed tumor growth (Fig. 4E ) and inhibited tumor regeneration (Fig. 4F) . Impressively, pLL3.7-let-7a also inhibited tumor development of the purified CD44 þ Du145 cells (Fig. 4G) .
The let-7 family miRNAs repress many oncogenic molecules including Ras, c-Myc, HMG, and Bcl-2 (27, 29, 30) . We observed that prostate cancer cells freshly transfected with the let-7b oligos exhibited significantly reduced c-Myc and K-Ras, both at the mRNA (Fig. 4H) and protein (Fig. 4I ) levels. Luciferase reporter assays confirmed K-Ras as a direct let-7 downstream target ( Supplementary Fig. S8 ). In contrast, the Bcl-2 mRNA and protein levels were not affected by let-7b ( Fig. 4H and I ).
miR-301 exerted differential biologic effects on different prostate cancer cells
We also probed for the biologic functions of one commonly overexpressed miRNA, that is, miR-301 (Supplementary Figs. S9 and S10). Unexpectedly, enforced miR-301 expression via oligo-transfection in purified CD44 À Du145 Shown are the expression levels (fold) relative to the corresponding NC control. C, the differences between miR-34 and let-7a or let-7b mRNA levels in LAPC9 cells were statistically significant (P < 0.05 for both; based on comparisons of the actual DDCt values). Also, the let-7b mRNA levels in A549 cells were significantly higher than those in LAPC9 (P ¼ 0.019; DDC t ) or in Du145 (P ¼ 0.049; DDC t ) cells. D, RNA levels of let-7a/b or miR-34a in endpoint LAPC9 or A549 tumors measured by qRT-PCR. Shown are the expression levels (fold) relative to the corresponding NC control. These endpoint tumors were derived from the corresponding transfected cells shown in A or C. E and F, overexpression of let-7a by lentiviral-mediated transduction significantly inhibited LAPC9 tumor development. Tumor sizes were measured by a caliber on the days indicated (E) and tumor images, average tumor weight, and incidence (parentheses) are presented (F). G, overexpression of let-7a inhibited tumor development from CD44 cells ( Supplementary Fig. S9A ) or knocking down endogenous miR-301 in CD44 þ Du145 cells ( Supplementary Fig.   S9B ) did not significantly affect sphere formation. Similar negative results were obtained in holoclone assays (Supplementary Fig. S9C and S9D ). miR-301 overexpression and knockdown were verified by quantitative PCR (qPCR; Supplementary Fig. S9E ). Manipulation of miR-301 levels also did not affect the tumor regeneration of CD44 þ /CD44 À Du145 cells ( Supplementary Fig. S9F-S9I) . Similarly, antimiR-301 oligos did not alter the clonal and tumorigenic properties of PC3 cells ( Supplementary Fig. S10A-S10C ). In contrast, enforced miR-301 expression promoted, whereas anti-miR-301 reduced the clonal and sphere-forming capacities of xenograft-derived LAPC9 cells ( Supplementary Fig.  S10D and S10E).
How miRNAs might be underexpressed in prostate cancer stem/progenitor cells? How tumor-suppressive miRNAs such as miR-34a and let-7 might be underexpressed in tumorigenic subpopulations is an interesting question. We attempted to address this question by focusing on miR-34a, whose expression is regulated in both p53-dependent and -independent mechanisms (47) . The miR34a levels in the 4 prostate cancer cell types with null or mutant p53 were significantly lower than those in the 6 prostate (cancer) cell types with wild-type (wt) p53 (22) . To explore whether the lower levels of miR-34a in tumorigenic prostate cancer cells might be related to lower p53 expression/activity, we treated p53-wt LNCaP cells with paclitaxel and 3 DNAdamaging agents, that is, doxorubicin, etoposide, and g-irradiation (X-ray). p53 was activated by etoposide and X-ray, as evidenced by both p53 protein accumulation (Fig. 5A ) and increased protein and mRNA levels of p21 ( Fig. 5A and B) , a p53 transcriptional target. When miR-34a (1p36.22) and miR-34b/c (11q23.1) levels were measured in treated LNCaP cells, we observed that miR-34a levels did not significantly change except a slight increase at 48 hours (Fig. 5C ). In contrast, both etoposide and X-ray increased miR-34b and miR-34c levels by several fold (Fig. 5C ). These observations suggest that underexpression of miR-34a in CD44
þ prostate cancer cells might not be related to p53 expression or activity. In support, the miR34a mRNA levels in the CD44 þ cells freshly purified from 14 primary HPCa cells did not correlate with p53 ( Supplementary  Fig. S11A and S11B) or p21 (not shown) mRNA levels. Previous studies suggest that c-Myc may positively regulate miR-34a (48) . However, the miR-34a mRNA levels in CD44 þ HPCa cells also did not correlate with c-Myc mRNA ( Supplementary Fig.  S11C ).
Discussion
For the first time, we have profiled the miRNA expression patterns in purified subpopulations of prostate cancer cells that possess stem/progenitor cell properties. Among the CD44
þ , side population, CD133 þ , and a2b1 þ cells studied, the CD44 þ prostate cancer cells are best characterized and have been consistently shown to enrich for tumor-initiating and prometastatic cells (6, 7, 22, 25) . The side population is also enriched in tumorigenic cells, although it is more rare (<0.1%) and detectable only in LAPC9 cells (12, 25 To establish whether the miRNAs identified in our miRNA library screening are functionally relevant, we have by far thoroughly studied 2 commonly underexpressed (i.e., miR34a and let-7b) and 1 commonly overexpressed (i.e., miR-301) miRNAs. Our earlier studies have uncovered a powerful role of miR-34a in restricting PCSC activity and prostate cancer regeneration/metastasis via repressing CD44 itself (22) . In the present study, we report similar prostate cancer-suppressive functions of let-7b/a. Our observations are in line with the widely recognized tumor-inhibitory effects of let-7a/b (27, 29, 30) and suggest that like miR-34a, the underexpressed let-7 normally functions to inhibit certain PCSC properties. An intriguing finding is that in prostate cancer cells, the transfected mature let-7a/b oligos seem to be degraded much more rapidly than miR-34a oligos, explaining why the former do not manifest obvious tumor-inhibitory effects. In fact, even prostate cancer cells infected with the pLL3.7-let-7a lentiviral vectors, which do manifest prostate cancer-inhibitory effects, keep low steady-state levels of let-7a (Liu and colleagues, unpublished observations). Coupled with the observations in A549 lung cancer cells, our work suggests that in prostate cancer, let-7 miRNAs have a faster turnover rate than other miRNAs such as miR-34a. Future work will further explore this potentially interesting phenomenon. Another interesting finding is that let-7 and miR-34a possess mechanistic differences in suppressing prostate cancer stem/progenitor cells: miR-34a induces G 1 cell-cycle arrest followed by cell senescence, whereas let-7 causes a prominent G 2 -M phase arrest without inducing senescence. Furthermore, miR-34a, but not let-7, induces apoptosis in some prostate cancer cells (22) . In support, let-7 overexpression does not affect the prosurvival molecule Bcl-2 (Fig. 4I) .
In contrast to consistent prostate cancer-inhibitory effects of miR-34a and let-7, miR-301, which is commonly overexpressed in prostate cancer stem/progenitor cells and recently shown to promote breast cancer cell proliferation and invasion (50) , seems to exhibit cell type-dependent effects. Although manipulation of miR-301 levels does not affect Du145 and PC3 cells, its overexpression promotes, whereas its knockdown inhibits the clonogenic properties of LAPC9 cells.
It will be of general interest to understand how certain miRNAs are differentially expressed in CSCs versus non-CSCs. Because the 2 populations are isogenic, it stands to reason that the differential expression results from epigenetic events rather than genetic mutations. Indeed, many tumor-suppressive miRNAs (e.g., miR-34a) are downregulated in cancer because of promoter hypermethylation or aberrant histone modifications. When we treated CD44 þ prostate cancer cells with 5-azadeoxycytidine and/or trichostatin A (an inhibitor of histone deacetylase), we did not observe any significant increase in miR-34 (Liu and colleagues, unpublished observations). The miR-34a levels also do not correlate with the 2 known upstream transcriptional regulators, that is, p53 and c-Myc. In fact, even in p53-wt bulk LNCaP cells, p53 activation does not consistently result in significant upregulation of miR-34a. Altogether, these observations argue that some other mechanisms might be operating to dampen miR-34a expression in PCSC-enriched cells. In summary, we have successfully conducted an miRNA expression profiling study in several prostate cancer stem/ progenitor cell populations, which has revealed both distinctively and commonly expressed miRNAs in tumorigenic prostate cancer cells. While shedding important light on how PCSCs may be regulated by miRNAs, our results converge with the emerging theme that distinct miRNAs both distinctively and coordinately regulate CSC properties (23) . Finally, our study establishes that tumor-suppressive miRNAs identified herein, such as miR-34a and let-7b/a, may represent novel therapeutics to specifically target CSCs and can be used in replacement therapy regimens. 
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